Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib 著者: Coombes, RC, Howell, S, Lord, SR, Kenny, L, Mansi, J, Mitri, Z, Palmieri, C, Chap, LI, Richards, P, Gradishar, W, Sardesai, S, Melear, J, O’Shaughnessy, J, Ward, P, Chalasani, P, Arkenau, T, Baird, RD, Jeselsohn, R, Ali, S, Clack, G, Bahl, A, McIntosh, S, Krebs, MG

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer 著者: Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH, Brugger, W, Harrington, EA, Evans, J, Hall, E, Tovey, H, De Oliveira, FM, Carreira, S, Swales, K, Ruddle, R, Raynaud, FI, Purchase, B, Dawes, JC, Parmar, M, Turner, AJ, Tunariu, N, Banerjee, S, De Bono, JS, Banerji, U